Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial - Kantarjian, Hagop M; Hochhaus, Andreas; Saglio, Giuseppe; Souza, Carmino De; Flinn, Ian W; Stenke, Leif; Goh, Yeow-Tee; Rosti, Gianantonio; Nakamae, Hirohisa; Gallagher, Neil J; Hoenekopp, Albert; Blakesley, Rick E; et al. (The lancet oncology, 2011)
Keywords: Administration, Oral; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Australia; Benzamides; Brazil; Disease-Free Survival; Drug Administration Schedule; Europe; Fusion Proteins, bcr-abl - antagonists & inhibitors; Fusion Proteins, bcr-abl - genetics; Fusion Proteins, bcr-abl - metabolism; Hematology, Oncology and Palliative Medicine; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Philadelphia Chromosome; Piperazines - administration & dosage; Piperazines - adverse effects; Piperazines - therapeutic use; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - genetics; Protein-Tyrosine Kinases - metabolism; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Singapore; Survival Rate; Time Factors; Treatment Outcome; United States; Brazil; Singapore; Australia; United States; Europe